Bio­theus builds on ADC pact with Han­soh; No­var­tis ex­pands in Sin­ga­pore; Astel­las leaves Carte­sian deal

Plus, news about Bio­con Bi­o­log­ics, Eris Life­sciences, Aprea Ther­a­peu­tics and Pi Health:

Bio­theus ex­pands ADC deal with Han­soh Phar­ma­ceu­ti­cal: Un­der the ex­tend­ed pact, Han­soh will get a li­cense to use an an­ti-EGFR/cMet bis­pe­cif­ic an­ti­body de­vel­oped by Bio­theus to cre­ate its own ADC prod­uct. Bio­theus could re­ceive up to RMB 5 bil­lion ($694 mil­lion) in up­front and mile­stones pay­ments, as well as tiered roy­al­ties on net sales. — Ay­isha Shar­ma

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.